Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

[1]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[2]  V. Diehl,et al.  Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Avilés,et al.  Gemcitabine and Cisplatin in Refractory Malignant Lymphoma , 2004, Oncology.

[4]  M. Territo,et al.  Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. , 2004, Clinical lymphoma.

[5]  S. Agelaki,et al.  High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. , 2004, Lung cancer.

[6]  A. Zelenetz,et al.  Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.

[7]  M. Arning,et al.  A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy , 2002, Investigational New Drugs.

[8]  J. Friedberg,et al.  Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease , 2003, Cancer.

[9]  G. Peters,et al.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines , 2003, British Journal of Cancer.

[10]  L. Greillier,et al.  Toxicité pulmonaire aiguë de la gemcitabine : un rôle pour l'exposition à l'amiante ? , 2003 .

[11]  D. Koh,et al.  Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM‐P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[12]  P. Rose,et al.  Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. , 2003, Gynecologic oncology.

[13]  F. Barlesi,et al.  [Acute pulmonary toxicity due to gemcitabine: a role for asbestos exposure?]. , 2003, Revue des maladies respiratoires.

[14]  B. Bonavida,et al.  Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. , 2002, Cancer biotherapy & radiopharmaceuticals.

[15]  N. Young,et al.  Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein. , 2002, Blood.

[16]  Dirk Hasenclever,et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.

[17]  D. Niedzwiecki,et al.  Long-term follow-up of Hodgkin's disease trial. , 2002, The New England journal of medicine.

[18]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[19]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[20]  A. Norman,et al.  An oxaliplatin‐based chemotherapy in patients with relapsed or refractory intermediate and high‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[21]  G. Peters,et al.  Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. , 2001, Biochemical pharmacology.

[22]  V. Diehl,et al.  Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Heitjan,et al.  Gemcitabine for relapsed or resistant lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  C. Bloomfield,et al.  The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 , 2000, Modern Pathology.

[26]  J. Diebold,et al.  THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES REPORT OF THE CLINICAL ADVISORY COMMITTEE MEETING , 2000 .

[27]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[28]  V. Diehl,et al.  Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. , 2000, Blood.

[29]  F. Gherlinzoni,et al.  Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. , 2000, Haematologica.

[30]  A. Zelenetz,et al.  Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Hiddemann,et al.  Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Bateman,et al.  Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  G. Peters,et al.  Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines , 1999, British Journal of Cancer.

[34]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Emile,et al.  Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  J. Blay,et al.  The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. , 1998, Blood.

[37]  A. Hagenbeek,et al.  Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Blay,et al.  A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. , 1998, Blood.

[39]  R. Bouabdallah,et al.  Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry , 1997, Bone Marrow Transplantation.

[40]  R. Stahel,et al.  Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  A. Demidem,et al.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.

[42]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Hagenbeek,et al.  77 Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin's disease six-year results of the EORTC-GPMC controlled clinical trials ‘H7-VF’, ‘H7-F’ and ‘H7-U’ , 1997 .

[44]  R. Bouabdallah,et al.  Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. , 1997, Bone marrow transplantation.

[45]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[46]  G. Peters,et al.  Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.

[47]  F. Berger,et al.  The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  S. Tucker,et al.  ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Fisher,et al.  A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[51]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[52]  H. Kantarjian,et al.  Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Jagannath,et al.  Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). , 1988, Blood.

[55]  J. Armitage,et al.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.